Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
March 29, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces Pricing of Public Offering of Common Stock
March 22, 2021 21:31 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces Proposed Public Offering of Common Stock
March 22, 2021 16:01 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...
Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan
March 17, 2021 07:00 ET
|
Verrica Pharmaceuticals Inc.
- Torii to make upfront payment of $11.5 million to Verrica in addition to other potential milestone payments of up to $58 million and, if marketed in Japan, tiered transfer price payments as a...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results
March 04, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
– FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021 – – Verrica Announces Torii Pharmaceutical Has Exercised Option to...
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
March 03, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
February 23, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
February 17, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
- PDUFA goal date assigned is June 23, 2021 - - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious...
Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference
January 19, 2021 07:00 ET
|
Verrica Pharmaceuticals Inc.
- In new post hoc analyses of the Phase 3 molluscum trials segmenting molluscum lesions by body region and study visit, the percentage of participants with complete clearance of all baseline and new...
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
December 23, 2020 16:01 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...